Certara, INC 10-K annual reports

Certara, Inc. announced a 9% increase in total revenues to $418.8 million and significantly reduced its net loss to $1.6 million for the fiscal year ended December 31, 2025, driven by strong demand and strategic acquisitions.

Certara's 2024 annual report highlights its position as a leader in biosimulation, focusing on growth strategies, financial performance, and strategic considerations including a review of its regulatory services business.

Certara, Inc. has filed an amendment to its 2023 annual report to explicitly state management's conclusion that its internal controls over financial reporting were effective as of December 31, 2023.

Certara Inc. released its annual 10-K filing, detailing its position as a leading provider of biosimulation technology and solutions for the biopharmaceutical industry.